全球标靶治疗市场研究报告 - 2024 年至 2032 年行业分析、规模、份额、成长、趋势和预测

全球标靶治疗市场需求预计将从 2023 年的 705.8 亿美元达到近 1,343 亿美元的市场规模，2024-2032 年研究期间CAGR为 7.41%。

标靶治疗是一类选择性针对疾病过程中涉及的特定分子或途径的医学治疗。与传统的广谱疗法不同，标靶疗法旨在提供精确有效的治疗，同时最大限度地减少对健康组织的不利影响。这些疗法通常利用单株抗体、小分子抑制剂、基因疗法或免疫疗法来干扰癌细胞生长、抑制异常讯号传导路径或调节免疫系统的反应。

市场动态

分子生物学和基因组学的进步使人们能够在分子层面上更深入地理解疾病机制，为开发能够精确靶向致病分子、最大限度地减少副作用和提高疗效的标靶疗法铺平了道路。此外，癌症、自体免疫疾病和心血管疾病等慢性疾病的发病率不断增加，增加了对更有效和个人化治疗方案的需求，进一步推动了标靶治疗市场的发展。此外，旨在加快标靶药物审批流程和製药公司增加研发投资的监管措施也促进了市场成长。此外，越来越多地采用伴随诊断来确定最有可能从标靶治疗中获益的个体，这正在提高市场渗透率。最后，次世代定序和基因编辑技术等技术进步为开发新型标靶疗法、促进创新和推动市场扩张开闢了新途径。然而，药物开发的监管挑战、高昂的研发成本以及来自既定治疗方式的竞争可能会限制标靶治疗市场。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球标靶治疗市场的每个细分市场进行了包容性评估。标靶治疗产业的成长和趋势为这项研究提供了整体方法。

市场区隔

标靶治疗市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

按类型

• 单株抗体（血管新生抑制剂、Her-2 标靶药物和抗 Cd20 单株抗体）
• 小分子（酪胺酸激酶抑制剂）

按申请

• 乳癌
• 大肠直肠癌
• 白血病
• 肺癌
• 淋巴瘤
• 多发性硬化症
• 肾癌
• 湿性老年黄斑部病变
• 其他（卵巢癌、输卵管癌、前列腺癌和胰腺癌）

按配销通路

• 医院药房
• 零售药局
• 网路药局

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲标靶治疗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。标靶治疗市场的主要参与者包括赛诺菲、葛兰素史克、武田药品工业株式会社、默克公司、诺华公司、辉瑞公司、罗氏公司、阿斯特捷利康、Seagen公司.、拜耳公司、安进公司、百时美施贵宝公司。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

• 报告说明
  • 客观的
  • 目标受众
  • 独特的销售主张 (USP) 和产品
• 研究范围
• 研究方法论
  • 市场研究过程
  • 市场研究方法论

第 2 章：执行摘要

• 市集亮点
• 全球市场概况

第 3 章：标靶治疗 - 产业分析

• 简介 - 市场动态
• 市场驱动因素
• 市场限制
• 机会
• 产业动态
• 波特五力分析
• 市场吸引力分析
  • 按类型分類的市场吸引力分析
  • 市场吸引力分析：依应用分类
  • 按配销通路分類的市场吸引力分析
  • 市场吸引力分析：按地区

第 4 章：价值链分析

• 价值链分析
• 原料分析
  • 原料清单
  • 原料厂商清单
  • 主要原物料价格走势
• 潜在买家名单
• 行销管道
  • 直效行销
  • 间接行销
  • 行销通路发展趋势

第 5 章：全球标靶治疗市场分析：按类型

• 按类型概述
• 历史和预测数据
• 按类型分析
• 单株抗体（血管新生抑制剂、HER-2标靶药物和抗CD20单株抗体）
• 小分子（酪胺酸激酶抑制剂）

第 6 章：全球标靶治疗市场分析：按应用分类

• 概述：按应用
• 历史和预测数据
• 分析：按应用
• 乳癌
• 大肠直肠癌
• 白血病
• 肺癌
• 淋巴瘤
• 多发性硬化症
• 肾癌
• 湿性老年黄斑部病变
• 其他（卵巢癌、输卵管癌、摄护腺癌、胰臟癌）

第 7 章：全球标靶治疗市场分析：按分销管道

• 按配销通路分類的概览
• 历史和预测数据
• 按配销通路分析
• 医院药房
• 零售药局
• 网路药局

第 8 章：全球标靶治疗市场分析：按地理位置

• 区域展望
• 介绍
• 北美销售分析
  • 概览、历史与预测资料销售分析
  • 北美按细分市场销售分析
  • 北美按国家销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概览、历史与预测资料销售分析
  • 欧洲按细分市场销售分析
  • 欧洲按国家销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 义大利销售分析
  • 俄罗斯销售分析
  • 欧洲其他地区销售分析
• 亚太地区销售分析
  • 概览、历史与预测资料销售分析
  • 亚太地区按细分市场销售分析
  • 亚太地区国家/地区销售分析
  • 中国销售分析
  • 印度销售分析
  • 日本销售分析
  • 韩国销售分析
  • 澳洲销售分析
  • 东南亚销售分析
  • 亚太地区其他地区销售分析
• 拉丁美洲销售分析
  • 概览、历史与预测资料销售分析
  • 拉丁美洲按细分市场销售分析
  • 拉丁美洲按国家销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利销售分析
  • 拉丁美洲其他地区销售分析
• 中东和非洲销售分析
  • 概览、历史与预测资料销售分析
  • 中东和非洲按细分市场销售分析
  • 中东和非洲国家销售分析
  • 沙乌地阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 中东其他地区和非洲销售分析

第 9 章：标靶治疗公司的竞争格局

• 标靶治疗市场竞争
• 伙伴关係/协作/协议
• 併购
• 新产品发布
• 其他发展

第 10 章：公司简介

• 公司股份分析
• 市场集中度
• Sanofi
• 公司简介
• 公司收入
• 产品
• 最近的发展
• GlaxoSmithKline plc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Takeda Pharmaceutical Company Ltd.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Merck & Co. Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Novartis AG
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Pfizer Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• F. Hoffmann-La Roche Ltd.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• AstraZeneca
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Seagen Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Bayer AG
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Amgen Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Bristol-Myers Squibb Company
• 公司简介
• 公司收入
• 产品
• 最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

The global demand for Targeted Therapeutics Market is presumed to reach the market size of nearly USD 134.3 Billion by 2032 from USD 70.58 Billion in 2023 with a CAGR of 7.41% under the study period 2024 - 2032.

Targeted therapeutics is a class of medical treatments that selectively target specific molecules or pathways involved in disease processes. Unlike traditional broad-spectrum therapies, targeted therapeutics aim to deliver precise and effective treatment while minimizing adverse effects on healthy tissues. These therapies often utilize monoclonal antibodies, small molecule inhibitors, gene therapies, or immunotherapies to interfere with cancer cell growth, inhibit abnormal signaling pathways, or modulate the immune system's response.

MARKET DYNAMICS

Progress in molecular biology & genomics has allowed for a more profound comprehension of disease mechanisms at the molecular level, paving the way for developing targeted therapies that can precisely target disease-causing molecules, minimizing side effects and improving efficacy. Additionally, the increasing incidence of chronic diseases such as cancer, autoimmune disorders, and cardiovascular diseases has increased the demand for more effective and personalized treatment options, further driving the market for targeted therapeutics. Moreover, regulatory initiatives aimed at expediting the approval process for targeted drugs and increasing investments in research and development by pharmaceutical companies are contributing to the market growth. Furthermore, the rising adoption of companion diagnostics to pinpoint individuals most likely to gain from targeted therapies is enhancing market penetration. Lastly, technological advancements such as next-generation sequencing and gene editing technologies open new avenues for developing novel targeted therapeutics, fostering innovation and driving market expansion. However, regulatory challenges in drug development, high research & development costs, and competition from established treatment modalities may restrict the targeted therapeutics Market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of targeted therapeutics. The growth and trends of targeted therapeutics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the targeted therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

• Monoclonal Antibodies (Angiogenesis Inhibitors, Her-2 Targeted Agents, And Anti-Cd20 Monoclonal Antibodies)
• Small Molecule (Tyrosine Kinase Inhibitors)

By Application

• Breast Cancer
• Colorectal Cancer
• Leukemia
• Lung Cancer
• Lymphoma
• Multiple Sclerosis
• Renal Cancer
• Wet Age-Related Macular Degeneration
• Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, And Pancreatic Cancer)

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Targeted Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Targeted Therapeutics market include Sanofi, GlaxoSmithKline plc., Takeda Pharmaceutical Company Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, Seagen, Inc., Bayer AG, Amgen, Inc., Bristol-Myers Squibb Company. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . TARGETED THERAPEUTICS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Type
  • 3.7.2 Market Attractiveness Analysis By Application
  • 3.7.3 Market Attractiveness Analysis By Distribution Channel
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL TARGETED THERAPEUTICS MARKET ANALYSIS BY TYPE

• 5.1 Overview by Type
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Type
• 5.4 Monoclonal Antibodies (Angiogenesis Inhibitors, HER-2 Targeted Agents, and Anti-CD20 Monoclonal Antibodies) Historic and Forecast Sales by Regions
• 5.5 Small Molecule (Tyrosine Kinase Inhibitors) Historic and Forecast Sales by Regions

6 . GLOBAL TARGETED THERAPEUTICS MARKET ANALYSIS BY APPLICATION

• 6.1 Overview by Application
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Application
• 6.4 Breast Cancer Historic and Forecast Sales by Regions
• 6.5 Colorectal Cancer Historic and Forecast Sales by Regions
• 6.6 Leukemia Historic and Forecast Sales by Regions
• 6.7 Lung Cancer Historic and Forecast Sales by Regions
• 6.8 Lymphoma Historic and Forecast Sales by Regions
• 6.9 Multiple Sclerosis Historic and Forecast Sales by Regions
• 6.10. Renal Cancer Historic and Forecast Sales by Regions
• 6.11 Wet Age-related Macular Degeneration Historic and Forecast Sales by Regions
• 6.12 Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, and Pancreatic Cancer) Historic and Forecast Sales by Regions

7 . GLOBAL TARGETED THERAPEUTICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 7.1 Overview by Distribution Channel
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Distribution Channel
• 7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
• 7.5 Retail Pharmacies Historic and Forecast Sales by Regions
• 7.6 Online Pharmacies Historic and Forecast Sales by Regions

8 . GLOBAL TARGETED THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2. North America By Segment Sales Analysis
  • 8.3.3. North America By Country Sales Analysis
  • 8.3.4. United State Sales Analysis
  • 8.3.5. Canada Sales Analysis
  • 8.3.6. Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2. Europe by Segment Sales Analysis
  • 8.4.3. Europe by Country Sales Analysis
  • 8.4.4. United Kingdom Sales Analysis
  • 8.4.5. France Sales Analysis
  • 8.4.6. Germany Sales Analysis
  • 8.4.7. Italy Sales Analysis
  • 8.4.8. Russia Sales Analysis
  • 8.4.9. Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2. Asia Pacific by Segment Sales Analysis
  • 8.5.3. Asia Pacific by Country Sales Analysis
  • 8.5.4. China Sales Analysis
  • 8.5.5. India Sales Analysis
  • 8.5.6. Japan Sales Analysis
  • 8.5.7. South Korea Sales Analysis
  • 8.5.8. Australia Sales Analysis
  • 8.5.9. South East Asia Sales Analysis
  • 8.5.10. Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2. Latin America by Segment Sales Analysis
  • 8.6.3. Latin America by Country Sales Analysis
  • 8.6.4. Brazil Sales Analysis
  • 8.6.5. Argentina Sales Analysis
  • 8.6.6. Peru Sales Analysis
  • 8.6.7. Chile Sales Analysis
  • 8.6.8. Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2. Middle East & Africa by Segment Sales Analysis
  • 8.7.3. Middle East & Africa by Country Sales Analysis
  • 8.7.4. Saudi Arabia Sales Analysis
  • 8.7.5. UAE Sales Analysis
  • 8.7.6. Israel Sales Analysis
  • 8.7.7. South Africa Sales Analysis
  • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE TARGETED THERAPEUTICS COMPANIES

• 9.1. Targeted Therapeutics Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10 . COMPANY PROFILES OF TARGETED THERAPEUTICS INDUSTRY

• 10.1. Company Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Sanofi
  • 10.3.1. Company Overview
  • 10.3.2. Company Revenue
  • 10.3.3. Products
  • 10.3.4. Recent Developments
• 10.4. GlaxoSmithKline plc.
  • 10.4.1. Company Overview
  • 10.4.2. Company Revenue
  • 10.4.3. Products
  • 10.4.4. Recent Developments
• 10.5. Takeda Pharmaceutical Company Ltd.
  • 10.5.1. Company Overview
  • 10.5.2. Company Revenue
  • 10.5.3. Products
  • 10.5.4. Recent Developments
• 10.6. Merck & Co. Inc.
  • 10.6.1. Company Overview
  • 10.6.2. Company Revenue
  • 10.6.3. Products
  • 10.6.4. Recent Developments
• 10.7. Novartis AG
  • 10.7.1. Company Overview
  • 10.7.2. Company Revenue
  • 10.7.3. Products
  • 10.7.4. Recent Developments
• 10.8. Pfizer Inc.
  • 10.8.1. Company Overview
  • 10.8.2. Company Revenue
  • 10.8.3. Products
  • 10.8.4. Recent Developments
• 10.9. F. Hoffmann-La Roche Ltd.
  • 10.9.1. Company Overview
  • 10.9.2. Company Revenue
  • 10.9.3. Products
  • 10.9.4. Recent Developments
• 10.10. AstraZeneca
  • 10.10.1. Company Overview
  • 10.10.2. Company Revenue
  • 10.10.3. Products
  • 10.10.4. Recent Developments
• 10.11. Seagen Inc.
  • 10.11.1. Company Overview
  • 10.11.2. Company Revenue
  • 10.11.3. Products
  • 10.11.4. Recent Developments
• 10.12. Bayer AG
  • 10.12.1. Company Overview
  • 10.12.2. Company Revenue
  • 10.12.3. Products
  • 10.12.4. Recent Developments
• 10.13. Amgen Inc.
  • 10.13.1. Company Overview
  • 10.13.2. Company Revenue
  • 10.13.3. Products
  • 10.13.4. Recent Developments
• 10.14. Bristol-Myers Squibb Company
  • 10.14.1. Company Overview
  • 10.14.2. Company Revenue
  • 10.14.3. Products
  • 10.14.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Type (USD MN)
• Monoclonal Antibodies (Angiogenesis Inhibitors, HER-2 Targeted Agents, and Anti-CD20 Monoclonal Antibodies) Market Sales by Geography (USD MN)
• Small Molecule (Tyrosine Kinase Inhibitors) Market Sales by Geography (USD MN)
• Analysis Market by Application (USD MN)
• Breast Cancer Market Sales by Geography (USD MN)
• Colorectal Cancer Market Sales by Geography (USD MN)
• Leukemia Market Sales by Geography (USD MN)
• Lung Cancer Market Sales by Geography (USD MN)
• Lymphoma Market Sales by Geography (USD MN)
• Multiple Sclerosis Market Sales by Geography (USD MN)
• Renal Cancer Market Sales by Geography (USD MN)
• Wet Age-related Macular Degeneration Market Sales by Geography (USD MN)
• Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, and Pancreatic Cancer) Market Sales by Geography (USD MN)
• Analysis by Distribution Channel (USD MN)
• Hospital Pharmacies Market Sales by Geography (USD MN)
• Retail Pharmacies Market Sales by Geography (USD MN)
• Online Pharmacies Market Sales by Geography (USD MN)
• Global Targeted Therapeutics Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Targeted Therapeutics Report
• Market Research Process
• Market Research Methodology
• Global Targeted Therapeutics Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Type
• Market Attractiveness Analysis by Application
• Market Attractiveness Analysis by Distribution Channel
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Type (USD MN)
• Monoclonal Antibodies (Angiogenesis Inhibitors, HER-2 Targeted Agents, and Anti-CD20 Monoclonal Antibodies) Market Sales by Geography (USD MN)
• Small Molecule (Tyrosine Kinase Inhibitors) Market Sales by Geography (USD MN)
• Global Market Analysis by Application (USD MN)
• Breast Cancer Market Sales by Geography (USD MN)
• Colorectal Cancer Market Sales by Geography (USD MN)
• Leukemia Market Sales by Geography (USD MN)
• Lung Cancer Market Sales by Geography (USD MN)
• Lymphoma Market Sales by Geography (USD MN)
• Multiple Sclerosis Market Sales by Geography (USD MN)
• Renal Cancer Market Sales by Geography (USD MN)
• Wet Age-related Macular Degeneration Market Sales by Geography (USD MN)
• Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, and Pancreatic Cancer) Market Sales by Geography (USD MN)
• Global Market Analysis by Distribution Channel (USD MN)
• Hospital Pharmacies Market Sales by Geography (USD MN)
• Retail Pharmacies Market Sales by Geography (USD MN)
• Online Pharmacies Market Sales by Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.